Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04028245
Title A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1)
Acronym SPARC-1
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Charles G. Drake
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.